Preparation and optimization of new 4-(morpholin-4-yl)-(6-oxo-1,6- dihydropyrimidin-2-yl)amide derivatives as PI3Kβ inhibitors

Victor Certal, Frank Halley, Angela Virone-Oddos, Fabienne Thompson, Bruno Filoche-Rommé, Youssef El-Ahmad, Jean Christophe Carry, Cécile Delorme, Andreas Karlsson, Pierre Yves Abecassis, Loic Vincent, Hélène Bonnevaux, Jean Paul Nicolas, Renaud Morales, Nadine Michot, Isabelle Vade, Audrey Louboutin, Sébastien Perron, Gilles Doerflinger, Bernadette TricSylvie Monget, Christoph Lengauer, Laurent Schio

Research output: Contribution to journalArticlepeer-review

Abstract

From a HTS campaign, a new series of pyrimidone anilides exemplified by compound 1 has been identified with good inhibitory activity for the PI3Kβ isoform. The structure of compound 1 in PI3Kγ was solved revealing a binding mode in agreement with the SAR observed on PI3Kβ. These compounds displayed inhibition in the nanomolar range in the biochemical assay and were also potent p-Akt inhibitors in a PTEN-deficient PC3 prostate cancer cell line. Optimization of in vitro pharmocokinetic properties led to compound 25 exhibiting 52% bioavailability in mice and target engagement in an acute PK/PD study.

Original languageEnglish (US)
Pages (from-to)6381-6384
Number of pages4
JournalBioorganic and Medicinal Chemistry Letters
Volume22
Issue number20
DOIs
StatePublished - Oct 15 2012
Externally publishedYes

Keywords

  • Kinase inhibitor
  • pAkt
  • PI3Kβ
  • PTEN
  • Pyrimidone anilide

ASJC Scopus subject areas

  • Pharmaceutical Science
  • Drug Discovery
  • Organic Chemistry
  • Molecular Medicine
  • Molecular Biology
  • Clinical Biochemistry
  • Biochemistry

Fingerprint Dive into the research topics of 'Preparation and optimization of new 4-(morpholin-4-yl)-(6-oxo-1,6- dihydropyrimidin-2-yl)amide derivatives as PI3Kβ inhibitors'. Together they form a unique fingerprint.

Cite this